GB201414403D0 - Pluripotent germ layer origin antigen presenting cancer vaccine - Google Patents

Pluripotent germ layer origin antigen presenting cancer vaccine

Info

Publication number
GB201414403D0
GB201414403D0 GBGB1414403.4A GB201414403A GB201414403D0 GB 201414403 D0 GB201414403 D0 GB 201414403D0 GB 201414403 A GB201414403 A GB 201414403A GB 201414403 D0 GB201414403 D0 GB 201414403D0
Authority
GB
United Kingdom
Prior art keywords
antigen presenting
cancer vaccine
germ layer
pluripotent germ
presenting cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB1414403.4A
Other languages
English (en)
Other versions
GB2512558A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NeoStem Oncology LLC
Original Assignee
California Stem Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by California Stem Cells Inc filed Critical California Stem Cells Inc
Publication of GB201414403D0 publication Critical patent/GB201414403D0/en
Publication of GB2512558A publication Critical patent/GB2512558A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
GB1414403.4A 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine Withdrawn GB2512558A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261594304P 2012-02-02 2012-02-02
PCT/US2013/024123 WO2013116505A1 (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Publications (2)

Publication Number Publication Date
GB201414403D0 true GB201414403D0 (en) 2014-10-01
GB2512558A GB2512558A (en) 2014-10-01

Family

ID=48905824

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1414403.4A Withdrawn GB2512558A (en) 2012-02-02 2013-01-31 Pluripotent germ layer origin antigen presenting cancer vaccine

Country Status (13)

Country Link
US (1) US20150064217A1 (enExample)
EP (1) EP2809775B1 (enExample)
JP (1) JP2015506698A (enExample)
KR (1) KR20140143361A (enExample)
CN (1) CN104540937A (enExample)
AU (1) AU2013215116A1 (enExample)
CA (1) CA2863653A1 (enExample)
GB (1) GB2512558A (enExample)
HK (2) HK1209455A1 (enExample)
IL (1) IL233928A0 (enExample)
NZ (1) NZ628292A (enExample)
SG (1) SG11201404543UA (enExample)
WO (2) WO2013116505A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103599528B (zh) * 2013-12-04 2015-08-05 深圳市合一康生物科技股份有限公司 人树突状细胞疫苗的制备方法
ES2882827T3 (es) 2014-10-07 2021-12-02 Cytlimic Inc Péptido inductor de inmunidad derivado de HSP70
RU2759728C2 (ru) 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
CN110198717A (zh) * 2017-01-11 2019-09-03 国立研究开发法人国立癌症研究中心 免疫治疗药
CA3053939A1 (en) * 2017-02-17 2018-08-23 Aivita Biomedical, Inc. Methods to enhance tumor immunogenicity and compositions for autologous cancer immunotherapeutic products using modified tumor cells and modified dendritic cells

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
CN1636229B (zh) * 2001-09-06 2012-12-19 西北生物治疗药物公司 引发单核树突细胞和t细胞th-1应答的组合物和方法
JP5623004B2 (ja) * 2004-10-25 2014-11-12 ベイラー リサーチ インスティテュートＢａｙｌｏｒ Ｒｅｓｅａｒｃｈ Ｉｎｓｔｉｔｕｔｅ 熱ショックをかけたメラノーマ細胞体が装填された樹状細胞
KR20130118998A (ko) * 2005-07-29 2013-10-30 프로비던스 헬스 앤드 서비시즈, 오레곤 수포에 담긴 불완전 리보솜 생성물（ＤＲｉｂｂｌｅ） 및 면역 반응을 자극하기 위해 이를 이용하는 방법
WO2008039969A2 (en) * 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US20090041792A1 (en) * 2007-07-19 2009-02-12 Istituto Superiore Di Sanita Dendritic cells, uses therefor, and vaccines and methods comprising the same

Also Published As

Publication number Publication date
WO2013116505A1 (en) 2013-08-08
SG11201404543UA (en) 2014-08-28
EP2809775A1 (en) 2014-12-10
EP2809775A4 (en) 2015-07-01
GB2512558A (en) 2014-10-01
NZ628292A (en) 2016-09-30
AU2013215116A1 (en) 2014-08-21
IL233928A0 (en) 2014-09-30
JP2015506698A (ja) 2015-03-05
US20150064217A1 (en) 2015-03-05
CA2863653A1 (en) 2013-08-08
WO2013116541A1 (en) 2013-08-08
HK1202432A1 (en) 2015-10-02
EP2809775B1 (en) 2018-06-13
HK1209455A1 (en) 2016-04-01
KR20140143361A (ko) 2014-12-16
CN104540937A (zh) 2015-04-22

Similar Documents

Publication Publication Date Title
ZA201500784B (en) Mycobacterial antigen vaccine
IL235890A0 (en) vaccine
SG10201610251PA (en) Compositions and methods for cancer immunotherapy
ZA201306944B (en) Individualized vaccines for cancer
GB201223386D0 (en) Vaccine
SG11201500396TA (en) Tumor vaccination
SG10201508535RA (en) Antigen Presenting Cancer Vaccine
GB201003293D0 (en) Cancer vaccine
IL233928A0 (en) A pluripotent germ layer-derived antigen with anti-cancer properties
PL2714071T3 (pl) Zindywidualizowane szczepionki przeciwrakowe
PL2591798T3 (pl) Szczepionka do zastosowania w immunoterapii nowotworów
ZA201407309B (en) Antigens and antigen combinations
GB201210226D0 (en) Vaccine
GB201202090D0 (en) Vaccine
GB201107549D0 (en) Cancer vaccine
GB201217321D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine
GB201207385D0 (en) Antigens and antigen combinations
GB201207383D0 (en) Antigens and antigen combinations
GB201216749D0 (en) Antigen combinations
GB201200568D0 (en) Antigen combinations

Legal Events

Date Code Title Description
732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20141002 AND 20141008

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1202432

Country of ref document: HK

732E Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977)

Free format text: REGISTERED BETWEEN 20180308 AND 20180314

WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1202432

Country of ref document: HK